{"filing":{"accession_number":"0001193125-26-292704","cik":"0001798749","ticker":"JBIO","company_name":"Jade Biosciences, Inc.","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"d145208d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526292704/d145208d8k.htm"},"events":[{"id":15568,"run_id":13889,"accession_number":"0001193125-26-292704","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Jade Biosciences entered into a material exclusive license agreement with Paragon Therapeutics on June 29, 2026, granting worldwide rights to develop and commercialize monospecific antibodies targeting an undisclosed therapeutic target. The agreement involves up to $22.0 million in development milestones and up to $20.1 million in sublicensing fees, plus royalties on future net sales. This is a strategic operational and commercial transaction material to the company's pipeline and business development, but does not constitute a merger, acquisition, or change of control (which would be classified as ma_activity), nor does it fit other specific financial or governance categories.","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13400,"accession_number":"0001193125-26-292704","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Jade Biosciences entered into a material exclusive license agreement with Paragon Therapeutics on June 29, 2026, granting worldwide rights to develop and commercialize monospecific antibodies targeting an undisclosed therapeutic target. The agreement involves up to $22.0 million in development milestones and up to $20.1 million in sublicensing fees, plus royalties on future net sales. This is a strategic operational and commercial transaction material to the company's pipeline and business development, but does not constitute a merger, acquisition, or change of control (which would be classified as ma_activity), nor does it fit other specific financial or governance categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:10:32.806740+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13400,"accession_number":"0001193125-26-292704","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Jade Biosciences entered into a material exclusive license agreement with Paragon Therapeutics on June 29, 2026, granting worldwide rights to develop and commercialize monospecific antibodies targeting an undisclosed therapeutic target. The agreement involves up to $22.0 million in development milestones and up to $20.1 million in sublicensing fees, plus royalties on future net sales. This is a strategic operational and commercial transaction material to the company's pipeline and business development, but does not constitute a merger, acquisition, or change of control (which would be classified as ma_activity), nor does it fit other specific financial or governance categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:10:32.806740+00:00","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-07-01"}]}